First Patient Treated in the ELMINATE Registrational Phase 2/3 Trial of LBP-EC01 for UTIs
Worldwide, an estimated 150 million people are affected by UTIs each year. The high prevalence of E. coli (80%), high rate of recurrence (40%), and growing rate of antimicrobial resistance to commonly used antibiotics (>25%) epitomizes the growing need for patients experiencing these infections. LBP-EC01 is engineered to meet these needs.
The Human
Microbiome
A collection of all the microbes that live on or in the human body, the microbiome plays an important role in your health. Day-to-day your microbiome helps digest your food, produce vitamins, regulate your immune system, and protect against other microbes that cause disease.
When the balance is disrupted, problematic microbes can take hold and cause or exacerbate:
- Infections like urinary tract infections (UTIs)
- Immunologic diseases like inflammatory bowel disease (IBD)
- Various types of cancer
Locus Biosciences builds precision medicines that target microbiome and address the unmet needs across bacterial infections, immunologic disorders, and cancer.
975 M
in signed deals
>1,000
bacteriophage engineered
4
programs targeting top global
MDR threats
About Us
Locus Biosciences is a precision medicine company that is developing bacteriophage-based products to precisely remove pathogenic bacteria from the human body and to leverage the microbiome to treat diseases across multiple therapeutic areas.
Our Partners
We are supported by an exceptional team of partners across academia,
government, large pharma, and investors.
